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Abstract
Esophageal adenocarcinoma risk in Barrett’s esophagus (BE) is increased 30- to 125-fold versus the
general population. Among all BE patients, however, neoplastic progression occurs only once per
200 patient-years. Molecular biomarkers are therefore needed to risk-stratify patients for more
efficient surveillance endoscopy and to improve the early detection of progression. We therefore
performed a retrospective, multicenter, double-blinded validation study of 8 BE progression
prediction methylation biomarkers. Progression or nonprogression were determined at 2 years (tier
1) and 4 years (tier 2). Methylation was assayed in 145 nonprogressors (NPs) and 50 progressors
(Ps) using real-time quantitative methylation-specific PCR. Ps were significantly older than NPs
(70.6 vs. 62.5 years, p < 0.001). We evaluated a linear combination of the 8 markers, using coefficients
from a multivariate logistic regression analysis. Areas under the ROC curve (AUCs) were high in
the 2-, 4-year and combined data models (0.843, 0.829 and 0.840; p<0.001, p<0.001 and p<0.001,
respectively). In addition, even after rigorous overfitting correction, the incremental AUCs
contributed by panels based on the 8 markers plus age vs. age alone were substantial (Δ-AUC = 0.152,
0.114 and 0.118, respectively) in all three models. A methylation biomarker-based panel to predict
neoplastic progression in BE has potential clinical value in improving both the efficiency of
surveillance endoscopy and the early detection of neoplasia.
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Barrett’s esophagus (BE) is a metaplastic condition where the normal squamous epithelium of
the lower esophagus is replaced by a small intestinal-like columnar lining(1). Esophageal
adenocarcinoma (EAC) risk in BE is increased 30- to 125-fold relative to the general population
(2), and endoscopic surveillance in BE patients is recommended at intervals of two to three
years(1,3). EACs detected in surveillance programs occur at earlier stages and have better
prognoses(4,5), but endoscopic surveillance suffers from high cost, inconvenience, patient
anxiety, low yield, and procedure-related risks. In addition, the current marker of EAC risk in
BE, dysplasia, is plagued by high inter-observer variability and limited predictive accuracy
(6-8). Because neoplastic progression is infrequent in BE, the merits of and appropriate interval
for endoscopic surveillance in BE have led to frequent debate(3,5). This process would benefit
greatly from effective biomarkers to stratify patients according to their level of neoplastic
progression risk.
In 2005, we reported that hypermethylation of p16, RUNX3, and HPP1 occurs early in BE-
associated neoplastic progression and predicts progression risk(9). Later, we developed a tiered
risk stratification model to predict progression in BE using epigenetic and clinical features
(10). We also studied methylation levels and frequencies of individual genes using real-time
quantitative methylation-specific PCR (qMSP) in 259 endoscopic esophageal biopsy
specimens of differing histologies. Among 10 genes evaluated, five, namely nel-like 1
(NELL1), tachykinin-1 (TAC1), somatostatin (SST), AKAP12, and CDH13, were methylated
early and often in BE-associated neoplastic progression(11-15). In the above studies,
methylation status and levels correlated inversely with mRNA expression levels (9-15). In light
of these findings, we performed a retrospective, multicenter, double-blinded validation study
of these 8 methylation biomarkers (i.e., p16, RUNX3, HPP1, NELL1, TAC1, SST, AKAP12,
and CDH13) for their accuracy in predicting neoplastic progression in BE.
Materials and Methods
Definition of Barrett’s esophagus progressor and nonprogressor patients and sample
collection
Progressors (Ps) and nonprogressors (NPs) were defined as described previously.(10) Ps were
considered both as a single combined group, and in two tiers: progression within 2 years (tier
1) or 4 years (tier 2). 195 BE biopsies (145 NPs and 50 Ps) were obtained from 5 participating
centers: the Mayo Clinic at Rochester/Jacksonville, the University of Arizona, the University
of North Carolina, and Johns Hopkins University. All patients provided written informed
consent under a protocol approved by Institutional Review Boards at their institutions. Biopsies
were taken using a standardized biopsy protocol. (9,10) Clinicopathologic features are
summarized in Supplementary Table 1.
Bisulfite Treatment and Real-Time Quantitative Methylation-Specific PCR (qMSP)
Bisulfite treatment was performed as described.(11) Promoter methylation levels of 8 genes
(p16, HPP1, RUNX3, CDH13, TAC1, NELL1, AKAP12 and SST) were determined by qMSP
on an ABI 7900 Sequence Detection (Taqman) System .(11) β-actin was used for
normalization. Primers and probes for qMSP are described in Supplementary Table 2. A
standard curve was generated using serial dilutions of CpGenome Universal Methylated DNA
(CHEMICON, Temecula, CA). A normalized methylation value (NMV) for each gene of
interest was defined as described.(11) Wetlab analysts (ZJ and YC) and all SJM laboratory
personnel were blinded to specimen P or NP status.
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Data Analysis and Statistics
Associations between progression status and patient characteristics were tested using Student’s
t-test or Chi-squared testing. Relationships between biomarkers and patient progression status
were examined using Wilcoxon rank-sum testing.
To evaluate the predictive utility of the markers, we constructed receiver operating
characteristic (ROC) curves. ROC curve analyses were first conducted on individual markers,
then in combination to determine whether a panel performed better than any single marker.
Our algorithm rendered a single composite score, using the linear predictor from a binary
regression model justified under the linearity assumption(16). The predictive accuracy of
composite scores was evaluated based on a resampling algorithm: we randomly split data into
a learning set containing 2/3 and a test set including 1/3 of observations. The combination rule
derived from the learning set produced two ROC curves, from the learning and test sets,
respectively. Vertical differences between these two ROC curves yielded the overestimation
of sensitivities at given specificities. This procedure was repeated 200 times, and these 200
differences were averaged to estimate the expected overfitting.
We also utilized predictiveness curves(17) to display risk distribution as a function of the
combined marker in the population. This curve represents a plot of risk associated with the
vth quantile of the marker, P{D=1|Y =F-1(v)} vs. v, with F(·) the cumulative distribution of the
marker. These plots display population proportions at different risk levels more clearly than
do other metrics (like ROC curves). Since a case-control sample was studied, we used an
external progression prevalence rate to calculate risk in the targeted screening population. To
calibrate for future samples, a shrinkage coefficient estimated from the logistic regression
model was applied to the linear predictors from which risk was calculated(18).
All analyses were performed in R (http://www.r-project.org). Statistical data analysts (Y.Z.,
W.G., and Z.F.) were blinded to the identities of the 8 biomarkers.
RESULTS
Clinical characteristics: Ps vs. NPs did not differ significantly by gender, body mass index,
BE segment length, LGD patient percentage,family history of BE, LGD, HGD or EAC,
cigarette smoking, or alcohol use; however, Ps were significantly older than NPs (70.6 vs. 62.5
years; p< 0.001, Student’s t test; Supplementary Table 1). Samples consisted of one biopsy
from each of 50 Ps and 145 NPs (195 patients) in the combined model. In the 2-year model,
we redefined progressors whose interval from index to final procedure exceeded 2 years as
nonprogressors, yielding 36 Ps and 159 NPs. In the 4-year model, we redefined progressors
whose interval from index to final procedure exceeded 4 years as nonprogressors, yielding 47
Ps and 148 NPs.
Univariate analyses: NMVs of HPP1, p16 and RUNX3 were significantly higher in Ps vs.
NPs by Wilcoxon test (0.456, 0.138, and 0.104 vs. 0.273, 0.069 and 0.063; p = 0.0025, 0.0066
and 0.0002, respectively). The remaining 5 markers did not differ significantly in Ps vs. NPs
(Supplementary Table 3). We further assessed the classification accuracy of single markers
using ROC curve analyses. Areas under ROC curve (AUCs) for HPP1, p16 and RUNX3 were
all significantly greater than 0.50, (Supplementary Table 4).
Logistic regression analyses of the 8-marker panel: We then combined all 8 markers by
performing logistic regression and treating them as linear predictors (Table 1, Supplementary
Figure 1). All models exhibited high AUCs (0.843, 0.829 and 0.840, respectively; Table 1,
Supplementary Figures 1A-1C). We performed overfitting correction based on 3-fold cross-
validation and 200 bootstraps. The overfitting-corrected AUCs remained high (0.745, 0.720
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and 0.732, respectively), while shrinkages from overfitting correction were modest (0.098,
0.109 and 0.108, respectively) in the three models (Table 1, Supplementary Figures 1A-1C).
We also explored the incremental AUC value contributed by an 8-marker-plus-age panel to
that of age alone (Table 2, Supplementary Figure 1). The AUCs of the 8-marker-plus-age panels
in the three models (0.858, 0.850 and 0.855, respectively) were higher than those of age alone
(0.604, 0.630 and 0.635, respectively; Table 2, Supplementary Figures 1D-1F). Overfitting-
corrected AUCs remained high (0.756, 0.744 and 0.753, respectively), and increments
contributed by the age-plus-biomarker panel vs. age were substantial (0.152, 0.114 and 0.118,
respectively) in the three models (Table 2, Supplementary Figures 1D-1F).
Sensitivity and specificity of the 8-marker panel: While maintaining high specificity to
minimize false-positive results, our model still predicted a number of new early diagnoses,
i.e., diagnoses that would not have occurred earlier without the panel (Table 3). While
maintaining specificity at 0.9 or 0.8, sensitivities (0.443 and 0.629 for the combined model,
0.607 and 0.721 for the 2-year model, and 0.465 and 0.606 for the 4-year model, respectively)
were above or approached 50% in all three models based on the 8-marker panel alone.
Furthermore, at 0.9 or 0.8 specificities, sensitivities (0.457 and 0.757 for the combined model,
0.536 and 0.786 for the 2-year model, and 0.450 and 0.724 for the 4-year model, respectively)
exceeded or approached 50% in all models based on the 8-marker-plus-age panel.
Risk stratification of BE patients: ROC curves derived from these marker-based models were
used to establish thresholds to stratify patients into risk categories. This procedure was
performed to identify high-risk (HR) individuals for more frequent endoscopic screening. The
threshold above which patients were classified as HR was chosen at specificity = 90%, to
minimize false-positive, unnecessary endoscopies (type II error). A second threshold was
established to identify low-risk (LR) individuals for less frequent endoscopic screening. The
threshold below which patients were classified as LR was chosen at sensitivity = 90%, to
minimize false-negative, missed HR individuals (type I error). Based on the combined P and
NP classification, we classified patients as LR with a threshold that corresponded to 90% true-
positives and 43% false-positives; the HR group was defined using a threshold that yielded
43% true-positives and 10% false-positives. Assuming a cumulative progression rate to HGD
and/or EAC of 7.5% over 5 years(19), the corresponding negative predictive value relating to
our LR threshold was 98.7% (i.e., progression risk in the LR group was 1.3%) and the positive
predictive value relating to HR was 27% (i.e., progression risk in the HR group was 27%).
Predictiveness curve analyses: We used predictiveness curves (also known as risk plots) to
assess the clinical utility of the combined classification rules in stratifying patients according
to risk levels in the target population. To create predictiveness curves, we ordered and plotted
risks from lowest to highest value. A progression rate to HGD and/or EAC of 7.5% over 5
years(19) was assumed in adjusting estimates from the case-control sample to reflect
population risk and its distribution. Results are shown in Table 4 and Supplementary Figure
2. After overfitting correction, by age alone, nearly 90% of BE patients were classified as
intermediate-risk (IR), whereas patients were well-stratified into low-risk (LR), IR, or high-
risk (HR) categories by both the 8-marker alone and age plus 8-marker panels in all three
models (Table 4, Supplementary Figure 2).
Discussion
In the current study, with specificity at 0.9, sensitivities of progression prediction approached
50% based on both the 8-marker panel alone and 8-marker-plus-age panel in all three models.
These findings indicate that even while performing at high specificity, these biomarker models
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predicted half of progressors to HGD and EAC that would not have been diagnosed earlier
without using these biomarkers.
Based on age alone, with specificity at 90%, only 17.6%, 23.2% and 22.1% of progressors
were predicted in the three models. However, with panels based on age plus biomarkers or on
biomarkers alone, approximately 60%, 50% and 50% of progressors were accurately predicted
in these three models. Predicted progressors represent patients in whom we can intercede
earlier, resulting in higher cure rates. Finally, our combined risk model outperformed known
risk in the general BE population (7.5% progression risk over 5 years), both in terms of negative
predictive value (1.3% progression risk over 5 years for the LR group) and positive predictive
value (27% progression risk over 5 years for the HR group).
Age is a common risk factor for many cancers, including EAC(20). In the current study, Ps
were significantly older than NPs, and the AUCs of age alone were 0.604, 0.630 and 0.635,
respectively in the three models, suggesting that age per se predicts neoplastic progression in
BE. However, methylation of tissues increases with aging, even in the absence of neoplastic
progression (21-22). Thus, aging may exert risk on progression either independently, or
through its influence on methylation. Nevertheless, the incremental prediction accuracy (above
age) contributed by the 8-marker panel was substantial in all three models.
Thus, the current findings suggest that this 8-marker panel is more objective and quantifiable
and possesses higher predictive sensitivity and specificity than do clinical features, including
age. Furthermore, although age was a good classifier for disease progression, predictiveness
curves revealed that age did not successfully stratify BE patients according to their progression
risk. Moreover, age per se is not an accepted risk marker on which to base clinical decisions
regarding surveillance interval or neoplastic progression risk in BE. In contrast, models based
on both the 8-marker panel and the age-plus-8-marker panel provided estimated progression
risks either close to 0 (i.e., LR) or between 0.1 and 0.5 (i.e., IR) in the majority of individuals,
suggesting that these markers exerted a substantial impact on risk category. This finding also
suggests that in clinical practice, separate thresholds can be chosen to define high, intermediate,
and low risk, based on predictiveness curves.
In conclusion, we have developed a risk stratification strategy to predict neoplastic progression
in BE patients based on an 8-marker tissue methylation panel. At high specificity levels, this
model accurately predicted approximately half of HGDs and EACs that would not have
otherwise been predicted. This model is expected to reduce endoscopic procedures performed
in BE surveillance while simultaneously increasing detection at earlier stages. Future studies
should explore additional potentially predictive methylation targets, along with alternative
means of assessing methylation biomarkers (such as immunohistochemical staining for
reduced biomarker expression). Thus, these findings suggest that a methylation biomarker
panel offers promise as a clinically useful tool in the risk stratification of BE patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Incremental values above age alone for the 2-year, 4-year and combined models




2-year model 0.604 (0.491, 0.718) 0.858 (0.783, 0.932) 0.756 (0.699, 0.884) 0.152
4-year model 0.630 (0.526, 0.735) 0.850 (0.784, 0.917) 0.744 (0.719, 0.871) 0.114
combined model 0.635 (0.532, 0.737) 0.855 (0.790, 0.919) 0.753 (0.729, 0.878) 0.118
AUC, area under the receiver-operator characteristic curve; AUC1, AUC of age alone;
AUC2, AUC of age plus markers; AUC3, overfitting corrected AUC of age plus markers; CI, confidence interval.
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Table 3
Specificity and sensitivity for 2-year, 4-year and combined models
Specificity (95% CI) at sensitivity= Sensitivity (95% CI) at specificity=
0.9 0.8 0.9 0.8
Combined model
 Age 0.260 (0.162, 0.425) 0.390 (0.240, 0.508) 0.221 (0.054, 0.448) 0.371 (0.204, 0.532)
 Marker combination 0.567 (0.413, 0.849) 0.724 (0.574, 0.914) 0.443 (0.350, 0.838) 0.629 (0.527, 0.941)
 Age+marker combination 0.576 (0.484, 0.867) 0.781 (0.647, 0.944) 0.457 (0.372, 0.869) 0.757 (0.598, 0.964)
2-year model
 Age 0.205 (0.138, 0.389) 0.351 (0.197, 0.484) 0.176 (0.021, 0.426) 0.354 (0.172, 0.538)
 Marker combination 0.547 (0.436, 0.873) 0.757 (0.595, 0.935) 0.607 (0.393, 0.870) 0.721 (0.593, 0.969)
 Age+markercombination 0.615 (0.474, 0.918) 0.786 (0.652, 0.956) 0.536 (0.400, 0.934) 0.786 (0.600, 0.987)
4-year model
 Age 0.249 (0.158, 0.430) 0.384 (0.229, 0.506) 0.232 (0.038, 0.467) 0.382 (0.214, 0.541)
 Marker combination 0.523 (0.426, 0.835) 0.704 (0.579, 0.909) 0.465 (0.346, 0.814) 0.606 (0.545, 0.941)
 Age+marker combination 0.574 (0.488, 0.864) 0.757 (0.649, 0.940) 0.450 (0.385, 0.885) 0.724 (0.600, 0.963)
CI, confidence interval
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Table 4
Overfitting-corrected predictiveness curve analyses in 2-year, 4-year and combined models
Risk probability
<0.1 (LR) 0.1-0.5 (IR) >0.5 (HR)
Combined model
 8-marker panel 45% 51% 4%
 age alone 15% 85% 0%
 age plus 8-marker panel 51% 44% 5%
2-year model
 8-marker panel 45% 51% 4%
 age alone 11% 89% 0%
 age plus 8-marker panel 52% 44% 4%
4-year model
 8-marker panel 44% 51% 5%
 age alone 15% 85% 0%
 age plus 8-marker panel 51% 44% 5%
LR, low-risk; IR, intermediate-risk; HR, high-risk.
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